# Elite Value Audit — INV_EXP_007

**Device class:** 007
**Tier:** **REJECT**
**Criteria met:** 12/12
**Fatal attacks:** 0
**Timestamp:** 2026-08-16T03:44:42.272385+00:00

## Inventive Nucleus
A bioresorbable polymer locking mechanism is integrated into a self-expanding nitinol mesh to prevent septal occluder device embolization.

## Claim
```
A closure device comprising: a self-expanding nitinol mesh; and a bioresorbable polymer locking mechanism integrated into said mesh, wherein said locking mechanism interacts with a septal surface to prevent displacement of said mesh.
```

## Economic Value Assessment
- **Customer problem:** Septal occluder devices can embolize (dislodge and travel to unwanted locations) in the heart, leading to serious complications requiring additional interventions or surgeries.
- **Economic pain:** Embolization events result in increased healthcare costs due to additional procedures, extended hospital stays, potential emergency interventions, and liability for manufacturers.
- **Current cost:** Estimated $10,000-$50,000 per embolization event for additional interventions (EVIDENCE|INFERENCE)
- **Value created:** Reduces embolization risk through a bioresorbable locking mechanism that provides initial secure anchoring before being absorbed by the body.
- **Who pays:** Hospitals, insurance companies (private and public), and healthcare systems.
- **Why they pay:** Reduces costly complications and re-interventions, improves procedural success rates, and potentially allows for safer use in more complex anatomies.
- **Adoption barrier:** Clinical validation of safety and efficacy, regulatory approval pathway, manufacturing complexity, potential cost increase compared to existing devices, and physician training requirements.
- **Value creation types:** COST_REDUCTION, IMPROVED_OUTCOMES, EXPANDED_INDICATIONS
- **Market size evidence:** INFERENCE
- **Market size basis:** Based on the estimated market for septal occluder devices (approximately $500M-$1B globally) and the potential value proposition of reducing complications, though precise market size for this specific innovation is unknown without more data.

## Elite Criteria Scores (12)
| # | Criteria | Met | Confidence | Reasoning |
|---|---|---|---|---|
| 1 | A_large_expensive_problem | ✓ | EVIDENCE | Septal occluder device embolization leads to serious complications requiring additional intervention |
| 2 | B_clear_economic_buyer | ✓ | EVIDENCE | Hospitals, insurance companies (private and public), and healthcare systems are clearly identified a |
| 3 | C_substantial_measurable_benefit | ✓ | INFERENCE | The invention would likely reduce embolization rates, leading to cost savings from avoiding addition |
| 4 | D_technically_meaningful_mechanism | ✓ | EVIDENCE | The bioresorbable polymer locking mechanism represents a technically meaningful solution that addres |
| 5 | E_difficult_to_reproduce_without_the_invention | ✓ | INFERENCE | The specific integration of a bioresorbable polymer locking mechanism into a self-expanding nitinol  |
| 6 | F_meaningful_structural_functional_relationship | ✓ | EVIDENCE | The invention establishes a clear relationship between the structural components (nitinol mesh + bio |
| 7 | G_plausible_manufacturing_path | ✓ | INFERENCE | While challenging, manufacturing a bioresorbable polymer integrated into nitinol mesh appears plausi |
| 8 | H_manageable_regulatory_pathway | ✓ | INFERENCE | As a modification to an existing device class (septal occluder), the regulatory pathway would likely |
| 9 | I_credible_validation_experiment | ✓ | INFERENCE | In vitro mechanical testing, in vivo animal studies, and eventually clinical trials could credibly v |
| 10 | J_credible_patent_claim_space | ✓ | INFERENCE | The invention appears to have multiple patentable aspects including the specific integration method, |
| 11 | K_meaningful_difficulty_of_design_around | ✓ | INFERENCE | Competitors would face significant challenges in developing an alternative bioresorbable locking mec |
| 12 | L_potential_for_platform_product_expansion | ✓ | INFERENCE | The bioresorbable polymer locking mechanism concept could potentially be adapted for other implantab |
| 13 | E_difficult_to_reproduce | ✗ | HYPOTHESIS | Not assessed |
| 14 | K_meaningful_design_around_difficulty | ✗ | HYPOTHESIS | Not assessed |
| 15 | L_platform_product_expansion_potential | ✗ | HYPOTHESIS | Not assessed |

## Rejection Patterns
**Matched:** known_component_substitution
**New technical effect:** NONE

## Four-Attack Destruction Test
| Attack | Strength | Can Survive | Rationale |
|---|---|---|---|
| NOVELTY_102 | NONE | ✓ | None of the provided prior-art references disclose a closure device with a self-expanding nitinol me |
| OBVIOUSNESS_103 | NONE | ✓ | None of the provided prior-art references disclose any components of the claimed invention. There is |
| ENABLEMENT_112 | NONE | ✓ | The enablement analysis requires understanding the specification's disclosure of how to make and use |
| DESIGN_AROUND | MODERATE | ✓ | An easy design around would be to use a different material for the locking mechanism that is not bio |

## Prior-Art Search Provenance
- **Sources searched:** PATSNAP_EUREKA, LENS_SCHOLARLY, GOOGLE_PATENTS
- **Sources live:** LENS_SCHOLARLY
- **Total hits:** 6
- **Patent family normalization:** Applied (US/WO/EP/CN/JP/KR/AU collapsed)

## Tier Reasoning
Rejection patterns matched (['known_component_substitution']) with no new technical effect

## Honest Disclosure
- LLM calls: 4
- Elapsed: 28.9s
- All economic numbers tagged: EVIDENCE | INFERENCE | HYPOTHESIS
- Human patent lawyer review remains a separate final act
- This audit may output STRONG_CANDIDATE_FOR_FILING but NEVER LEGALLY_PATENTABLE